GenoME Diagnostics Ltd, a spin-out from Queen’s University Belfast, is focused on advancing the diagnostic landscape for ovarian cancer through its lead product, OvaME. This innovative blood test aims to facilitate earlier and more accurate diagnoses of ovarian cancer, addressing a critical need in the diagnostic pathway for this disease. The company leverages a decade of scientific research conducted at the Patrick G Johnston Centre for Cancer Research, ensuring that their approach is grounded in robust scientific evidence.

In addition to OvaME, GenoME Diagnostics is developing a pipeline that employs cutting-edge technologies for biomarker discovery and development across various diseases. Their commitment to creating user-friendly and cost-effective diagnostic solutions positions them to make significant contributions to the field of medical diagnostics, enhancing the ability to detect and monitor diseases effectively. This focus on innovation and accessibility underscores their mission to improve patient outcomes through advanced diagnostic methodologies.

Ireland

GenoME Diagnostics is a spinout from the prestigious Patrick G Johnston Centre for Cancer Research at Queen's University Belfast. We are developing novel blood tests for earlier and more accurate detection of ovarian and pancreatic cancers. GenoME Diagnostics aims to reduce the misdiagnosis and late detection to improve patient survival and outcome. 

Our pipeline could be applied to biomarker discovery and development in a wide range of diseases and applications.

GenoMe Diagnostics

Company Details